Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Idenix Pharmaceuticals Inc.
Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 1998
Status: Acquired
BioCentury | Oct 3, 2024
Finance
Kurma investing new fund; Kailera advancing obesity assets with $400M
BioCentury’s latest Venture Report also features news about LoQus23, Aktis, Resolution, Triveni, Flagship and more
BioCentury | Sep 20, 2024
Finance
Upstream enters IPO queue; Nuvalent follow-on balloons to $575M
Also in BioCentury’s weekly Public Equity Report: Ascendis follows up a data release with a $300M offering; BioAge proposes terms for listing
BioCentury | Dec 7, 2023
Deals
AbbVie sees Cerevel’s antipsychotic as ‘best-in-class’ driver of $8.7B deal
Again investing outside immunology, pharma sees differentiation in potential competitor with Karuna’s registrational schizophrenia therapy
BioCentury | Dec 6, 2023
Deals
Building again outside immunology, AbbVie buys Cerevel for $8.7B
On heels of ImmunoGen deal, pharma looks to Pfizer spinout led by Coles, Renaud to add neuroscience candidates nearing clinical readouts
BioCentury | May 3, 2023
Management Tracks
Culture and trust: How Cerevel’s Coles picked Renaud for CEO
Ahead of handful of milestones, former Translate Bio, Idenix CEO joining CNS company; Coles retaining chairman role
BioCentury | Oct 31, 2020
Finance
Data Byte: at $1.9B valuation, Atea leads this week’s IPOs
Atea led the pack of IPOs priced in the final week before the U.S. election, trading up 26% to $30.34 on its first day of trading Friday after raising $300 million. The upsized offering valued
BioCentury | Oct 27, 2020
Finance
With $1.8B valuation within reach, Sommadossi’s Atea readies ‘mega-IPO’
Cell therapy play SQZ also sets terms for NASDAQ IPO
BioCentury | Oct 23, 2020
Deals
Roche in $350M deal with Sommadossi’s Atea for what it believes could be first oral COVID-19 antiviral
Led by Idenix, Pharmasset co-founder, Atea is fresh off $215M round led by Bain
BioCentury | May 21, 2020
Finance
With repurposed antiviral, Atea draws $215M as it preps Phase II COVID-19 trial
BioCentury | Nov 30, 2018
Financial News
Pharmasset, Idenix vets lead HBV company Antios to $25M series A
Items per page:
1 - 10 of 336